Thirty-five percent of patients remaining on therapy in a second-line pancreatic adenocarcinoma study is not a number Can-Fite should bury — it is the entire commercial argument the company is taking to BIO International this week. That figure, alongside stable disease in more than 30% of evaluable patients and at least one patient crossing 16 months on treatment, gives namodenoson’s Phase 2a dataset just enough signal to make a partnership conversation credible, even if the data remain immature and the patient numbers small enough that a handful of durable responders can move percentages dramatically.
The strategic logic here is straightforward and slightly uncomfortable. Can-Fite is a micro-cap Israeli biotech with a NYSE American listing, a market cap that rarely clears $20 million, and a pipeline simultaneously running Phase 3 trials in hepatocellular carcinoma and MASH alongside the pancreatic program. It cannot self-fund a properly powered Phase 2b combination study in pancreatic cancer — a notoriously expensive indication given rapid disease progression and short survival windows. The BIO meetings, where the VP of Business Development is scheduled with undisclosed oncology companies already under confidentiality agreements, are not a courtesy tour. They are a financing event dressed as a partnership discussion. The Phase 2b design gets unveiled there precisely because a concrete protocol gives potential co-developers something to price, not just admire.
The combination with immunotherapy framing is where the science and the business rationale converge, and not entirely without merit. A3 adenosine receptor agonism has immunomodulatory properties that, in preclinical models, show plausible synergy with checkpoint inhibition — a mechanism that has largely failed in pancreatic cancer as a monotherapy but continues to attract combination-arm investment because the unmet need is acute enough to justify iterative attempts. Namodenoson’s clean safety profile across more than 1,600 patients in various studies means a pharma partner adding it to a PD-1 backbone carries limited toxicity risk. That is a real, if narrow, selling point.
The single number to watch out of BIO is not which company signs a term sheet, but whether Can-Fite discloses a median duration of treatment from the Phase 2a cohort — because that figure, more than any response rate, will determine whether the 35% still-on-therapy statistic reflects genuine disease control or simply slow enrollment and short follow-up.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
